{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:59:45Z","timestamp":1789192785857,"version":"build-2803163510"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic dysfunction\u2013associated steatotic liver disease (MASLD) has become a major comorbidity in patients with type 2 diabetes mellitus (T2DM). This study aimed to evaluate the diagnostic performance of the triglyceride-glucose\u2013body mass index (TyG-BMI), the C-reactive protein\u2013triglyceride\u2013glucose index (CTI), and the systemic immune-inflammation index (SII), individually and in combination, for identifying MASLD in patients with T2DM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cross-sectional study enrolled 796 hospitalized patients with T2DM from January 2020 to January 2025. Sample size was determined based on available eligible cases during the study period. Data distribution was assessed using the Kolmogorov\u2013Smirnov test. There were 280 MASLD patients and 516 non-MASLD patients. We collected anthropometric, biochemical, and inflammatory parameters. We performed correlation and multivariate logistic regression analyses to find independently associated factors. We evaluated diagnostic performance using receiver operating characteristic (ROC) curves, the area under the curve (AUC), and the Youden index. We also used net reclassification improvement (NRI) and integrated discrimination improvement (IDI) to assess predictive value. External validation was performed using an independent cohort of 394 patients. Key limitations include the retrospective design, potential misclassification due to ultrasound-based diagnosis, and residual confounding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      MASLD patients exhibited significantly higher BMI, triglycerides, low-density lipoprotein cholesterol (LDL-C), TyG-BMI, CTI, and SII levels than non-MASLD patients (all\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.05). TyG-BMI, CTI, and SII were independent MASLD predictors. The combined model (TyG-BMI\u202f+\u202fCTI\u202f+\u202fSII) had the highest discriminative power, outperforming each single indicator. Adding CTI and SII to TyG-BMI significantly improved classification (NRI\u202f=\u202f0.312, IDI\u202f=\u202f0.143, both\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.05). External validation indicated strong performance (AUC\u202f=\u202f0.940, sensitivity\u202f=\u202f84.6%, specificity\u202f=\u202f90.1%). Machine learning validation using a random forest algorithm further indicated the high predictive accuracy of the model, achieving an AUC of 0.950 in the development cohort and maintaining a robust AUC of 0.885 in the external validation cohort.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TyG-BMI, CTI, and SII are independently associated with MASLD in T2DM patients. Their combined use significantly improves early identification accuracy and could serve as a convenient, cost-effective screening tool in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnut.2026.1808180","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:54:42Z","timestamp":1778219682000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Predictive value of TyG-BMI, CTI, and SII in identifying metabolic dysfunction-associated steatotic liver disease among patients with type 2 diabetes mellitus"],"prefix":"10.3389","volume":"13","author":[{"given":"Yue","family":"Chen","sequence":"first","affiliation":[{"name":"Quality Control Department of Jiangbei Campus, The First Affiliated Hospital of Army Medical University (The 958th Hospital of the Chinese People's Liberation Army)","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayu","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Cardiology of Jiangbei Campus, The First Affiliated Hospital of Army Medical University (The 958th Hospital of the Chinese People's Liberation Army)","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qu","family":"Xiang","sequence":"additional","affiliation":[{"name":"Quality Control Department of Jiangbei Campus, The First Affiliated Hospital of Army Medical University (The 958th Hospital of the Chinese People's Liberation Army)","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Fan","sequence":"additional","affiliation":[{"name":"Infection Control Department of Jiangbei Campus, The First Affiliated Hospital of Army Medical University (The 958th Hospital of the Chinese People's Liberation Army)","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology of Jiangbei Campus, The First Affiliated Hospital of Army Medical University (The 958th Hospital of the Chinese People's Liberation Army)","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Gao","sequence":"additional","affiliation":[{"name":"Quality Control Department of Jiangbei Campus, The First Affiliated Hospital of Army Medical University (The 958th Hospital of the Chinese People's Liberation Army)","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfeng","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Luo","sequence":"additional","affiliation":[{"name":"The Office of Jiangbei Campus, The First Affiliated Hospital of Army Medical University (The 958th Hospital of the Chinese People's Liberation Army)","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejim.2023.11.005","article-title":"Natural history of metabolic dysfunction-associated steatotic liver disease","volume":"122","author":"Lekakis","year":"2024","journal-title":"Eur J Intern Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/apt.17846","article-title":"Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease","volume":"59","author":"Loomba","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s12933-024-02434-5","article-title":"Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review","volume":"23","author":"Zheng","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1097\/hep.0000000000001015","article-title":"Liver stiffness progression in biopsy-proven metabolic dysfunction-associated steatotic disease among people with diabetes versus people without diabetes: a prospective multicenter study","volume":"81","author":"Huang","year":"2025","journal-title":"Hepatology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3350\/cmh.2024.0631","article-title":"Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations","volume":"31","author":"Danpanichkul","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1136\/gutjnl-2023-330110","article-title":"Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis","volume":"72","author":"En Li Cho","year":"2023","journal-title":"Gut"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/s12933-024-02489-4","article-title":"Metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: risk of heart failure","volume":"23","author":"Oh","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s13679-024-00574-z","article-title":"Non-invasive scores and serum biomarkers for fatty liver in the era of metabolic dysfunction-associated steatotic liver disease (MASLD): a comprehensive review from NAFLD to MAFLD and MASLD","volume":"13","author":"Abdelhameed","year":"2024","journal-title":"Curr Obes Rep"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e240038","DOI":"10.1148\/radiol.240038","article-title":"Photon-counting detector CT for liver fat quantification: validation across protocols in metabolic dysfunction-associated steatotic liver disease","volume":"312","author":"Lin","year":"2024","journal-title":"Radiology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1097\/hep.0000000000001190","article-title":"Diagnostic accuracy of 2D-SWE ultrasound for liver fibrosis assessment in MASLD: a multilevel random effects model meta-analysis","volume":"82","author":"Indre","year":"2025","journal-title":"Hepatology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12933-024-02343-7","article-title":"Association between triglyceride-glucose related indices and mortality among individuals with non-alcoholic fatty liver disease or metabolic dysfunction-associated steatotic liver disease","volume":"23","author":"Chen","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"115350","DOI":"10.1016\/j.celrep.2025.115350","article-title":"Hexokinase 2-mediated metabolic stress and inflammation burden of liver macrophages via histone lactylation in MASLD","volume":"44","author":"Li","year":"2025","journal-title":"Cell Rep"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"155694","DOI":"10.1016\/j.metabol.2023.155694","article-title":"Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: a multicenter observational study","volume":"148","author":"Valenzuela-Vallejo","year":"2023","journal-title":"Metabolism"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12933-025-02869-4","article-title":"Associations of cumulative exposure and dynamic trajectories of the C-reactive protein-triglyceride-glucose index with incident cardiovascular disease in middle-aged and older Chinese adults: a nationwide cohort study","volume":"24","author":"Ma","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1331610","DOI":"10.3389\/fimmu.2024.1331610","article-title":"Systemic immune-inflammation index is associated with chronic kidney disease in the U.S. population: insights from NHANES 2007-2018","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.2337\/dc25-S002","article-title":"2. Diagnosis and classification of diabetes: standards of care in diabetes-2025","volume":"48","author":"Committee","year":"2025","journal-title":"Diabetes Care"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.jhep.2024.11.049","article-title":"A new generation of non-invasive tests of liver fibrosis with improved accuracy in MASLD","volume":"82","author":"Cal\u00e8s","year":"2025","journal-title":"J Hepatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.12182\/20240960103","article-title":"Association between triglyceride glucose index and triglyceride glucose-obesity composite indices and the risk of ischemic heart disease","volume":"55","author":"Yang","year":"2024","journal-title":"Sichuan Da Xue Xue Bao Yi Xue Ban"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1186\/s12888-024-06336-4","article-title":"Association between C-reactive protein-triglyceride glucose index and depressive symptoms in American adults: results from the NHANES 2005 to 2010","volume":"24","author":"Huang","year":"2024","journal-title":"BMC Psychiatry"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1115031","DOI":"10.3389\/fimmu.2023.1115031","article-title":"The clinical value of neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), platelet-to-lymphocyte ratio (PLR) and systemic inflammation response index (SIRI) for predicting the occurrence and severity of pneumonia in patients with intracerebral hemorrhage","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41398-018-0289-1","article-title":"Predicting the naturalistic course of depression from a wide range of clinical, psychological, and biological data: a machine learning approach","volume":"8","author":"Dinga","year":"2018","journal-title":"Transl Psychiatry"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1097\/hep.0000000000000913","article-title":"Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease","volume":"83","author":"Qi","year":"2024","journal-title":"Hepatology"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1007\/s00330-024-11119-2","article-title":"Comparing ultrasound-derived fat fraction and MRI-PDFF for quantifying hepatic steatosis: a real-world prospective study","volume":"35","author":"Qi","year":"2025","journal-title":"Eur Radiol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"840","DOI":"10.14309\/ajg.0000000000002020","article-title":"A reappraisal of the diagnostic performance of B-mode ultrasonography for mild liver steatosis","volume":"118","author":"Lee","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.3390\/nu16121925","article-title":"Malnutrition-related liver steatosis, CONUT score and poor clinical outcomes in an internal medicine department","volume":"16","author":"Miano","year":"2024","journal-title":"Nutrients"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.cgh.2014.08.039","article-title":"Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with nonalcoholic steatohepatitis","volume":"13","author":"Patel","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1053\/j.gastro.2025.02.034","article-title":"From \"burnt-out\" to \"burning-out\": capturing liver fat loss in patients with advanced metabolic dysfunction-associated steatotic liver disease from a dynamic perspective","volume":"169","author":"Liu","year":"2025","journal-title":"Gastroenterology"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1002\/hep.26340","article-title":"Adiponectin, bile acids, and burnt-out nonalcoholic steatohepatitis: new light on an old paradox","volume":"57","author":"Claudel","year":"2013","journal-title":"Hepatology"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12933-024-02572-w","article-title":"Association between triglyceride-glucose (TyG) related indices and cardiovascular diseases and mortality among individuals with metabolic dysfunction-associated steatotic liver disease: a cohort study of UK biobank","volume":"24","author":"Qiao","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"951689","DOI":"10.3389\/fendo.2022.951689","article-title":"Potential screening indicators for early diagnosis of NAFLD\/MAFLD and liver fibrosis: triglyceride glucose index-related parameters","volume":"13","author":"Xue","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejim.2024.08.026","article-title":"Triglyceride glucose (TyG) index: a promising biomarker for diagnosis and treatment of different diseases","volume":"131","author":"Sun","year":"2025","journal-title":"Eur J Intern Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12944-023-01954-5","article-title":"Application value of triglyceride-glucose index and triglyceride-glucose body mass index in evaluating the degree of hepatic steatosis in non-alcoholic fatty liver disease","volume":"22","author":"Wang","year":"2023","journal-title":"Lipids Health Dis"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12933-025-02686-9","article-title":"Association between C-reactive protein-triglyceride glucose index and stroke risk in different glycemic status: insights from the China health and retirement longitudinal study (CHARLS)","volume":"24","author":"Huo","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12876-025-03870-7","article-title":"Correlation between hs-CRP-triglyceride glucose index and NAFLD and liver fibrosis","volume":"25","author":"Zhou","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"e45777","DOI":"10.1097\/md.0000000000045777","article-title":"Association between C-reactive protein-triglyceride glucose index and NAFLD in US adults: a nationally cross-sectional study using NHANES 2017-2020 data","volume":"104","author":"Chen","year":"2025","journal-title":"Medicine (Baltimore)"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12933-025-02818-1","article-title":"Interpretable machine learning analysis of immunoinflammatory biomarkers for predicting CHD among NAFLD patients","volume":"24","author":"Dong","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1337241","DOI":"10.3389\/fimmu.2024.1337241","article-title":"Systemic immune-inflammatory biomarkers (SII, NLR, PLR and LMR) linked to non-alcoholic fatty liver disease risk","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1566345","DOI":"10.3389\/fnut.2025.1566345","article-title":"Mediating role of systemic immune-inflammation index between heavy metal exposure and hepatic steatosis\/hepatic fibrosis: evidence from NHANES 2005-2020","volume":"12","author":"Wang","year":"2025","journal-title":"Front Nutr"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"15473","DOI":"10.3390\/ijms242015473","article-title":"Metabolic-dysfunction-associated steatotic liver disease-its pathophysiology, association with atherosclerosis and cardiovascular disease, and treatments","volume":"24","author":"Yanai","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1161\/circresaha.121.318093","article-title":"Obesity, adipose tissue and vascular dysfunction","volume":"128","author":"Koenen","year":"2021","journal-title":"Circ Res"}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1808180\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:54:43Z","timestamp":1778219683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1808180\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":42,"alternative-id":["10.3389\/fnut.2026.1808180"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2026.1808180","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"article-number":"1808180"}}